BRD4(BD1)/H4 Binding Assay Kit: From TR-FRET Principle to High-Throughput Screening of Small Molecule Inhibitors

Author: Senior Product Manager of UA Views：13

This article systematically elucidates the molecular basis of BRD4 bromodomain recognition of histone H4 acetylation modifications and its central role in gene transcription regulation, focusing on the technical principles and application systems of the BRD4(BD1)/H4 binding detection kit. It analyzes the detection principle and signal generation mechanism based on homogeneous time-resolved fluorescence resonance energy transfer (HTRF) technology and explores the application strategies of this kit in evaluating small molecule-mediated protein-peptide interactions and high-throughput screening.

Recent Advances
Product Information

Recent Advances

BRD4(BD1)/H4 Binding Assay Kit: From TR-FRET Principle to High-Throughput Screening of Small Molecule Inhibitors

Overview
This article systematically elaborates on the molecular basis of BRD4 bromodomain recognition of histone H4 acetylation modification and its central role in gene transcription regulation, analyzes the detection principle and signal generation mechanism based on homogeneous time-resolved fluorescence resonance energy transfer technology, and discusses the application strategies of this assay kit in the evaluation of small molecule-mediated protein-peptide interactions and high-throughput screening.

I. Molecular Structure of BRD4 and Its Central Role in Gene Transcription Regulation

BRD4 (Bromodomain-containing protein 4) is a member of the bromodomain and extraterminal domain family and plays a key role in gene transcription regulation. The BRD4 protein contains two tandem bromodomains, BD1 and BD2, each consisting of approximately 110 amino acid residues and forming a characteristic four-helix bundle fold structure. The core function of the bromodomain is to specifically recognize and bind acetylation modifications on histone lysine residues, with BD1 exhibiting high affinity for acetylation modifications at lysine residues 5 and 8 of histone H4. After binding to acetylated histones via its bromodomains, BRD4 recruits the positive transcription elongation factor complex to regulate the transcription elongation process of RNA polymerase II, thereby driving the expression of key oncogenes such as MYC and BCL-2. Abnormal activation of BRD4 is closely associated with the development of various hematological malignancies and solid tumors, making it one of the most prominent targets in the field of epigenetic-targeted therapy. Therefore, precise detection of the interaction between BRD4 and its natural ligands is a fundamental technical requirement for the development of BRD4 inhibitors.

II. Technical Principle of BRD4(BD1)/H4 Binding Assay

This assay kit is based on homogeneous time-resolved fluorescence resonance energy transfer technology and is used to evaluate small molecule-mediated interactions between BRD4 (BD1) and H4 peptides. The method provides a high-throughput approach for simple and rapid detection of small molecules that can mediate the interaction between BRD4 (BD1) and H4 peptide fragments. The core of TR-FRET technology lies in detecting energy transfer between two fluorescently labeled molecules: when the donor molecule is excited, if the donor and acceptor molecules are within a close range of 5 to 10 nanometers, energy is transferred from the donor to the acceptor via fluorescence resonance energy transfer, generating a specific fluorescence signal.

Specifically, the interaction between BRD4 (BD1) and H4 peptide is detected by an Eu-labeled anti-Tag1 antibody (TR-FRET donor) and an Ac-labeled anti-Tag2 antibody (TR-FRET acceptor). When the donor and acceptor antibodies are in close proximity, excitation of the donor antibody triggers fluorescence resonance energy transfer to the acceptor antibody, resulting in a specific signal emitted at 665 nm from the acceptor antibody. This specific signal is proportional to the degree of interaction between BRD4 (BD1) and H4 peptide fragments, with higher signal intensity indicating stronger binding between BRD4(BD1) and H4 peptide, and vice versa indicating inhibited binding. This homogeneous assay is simple to operate, requires no washing steps, and is suitable for high-throughput screening scenarios.

III. Core Advantages and Signal Characteristics of TR-FRET Technology

TR-FRET technology uses lanthanides (such as europium Eu) as donors, which exhibit large Stokes shifts and long fluorescence lifetimes in the millisecond range, enabling time-delayed detection. By setting a delay time after excitation and reading the signal after short-lived background fluorescence has decayed, the technology avoids interference from excitation light scattering and eliminates background noise caused by medium components and protein autofluorescence, significantly improving detection accuracy. Additionally, lanthanide donors offer excellent photostability and batch-to-batch consistency, making them suitable for long-term high-throughput screening operations.

In the BRD4(BD1)/H4 binding assay system, when small molecule inhibitors (such as JQ-1) block the interaction between BRD4 (BD1) and H4 peptide, the distance between the donor and acceptor antibodies increases, reducing the FRET signal. This signal change can be quantitatively analyzed through dose-response curves to calculate the half-maximal inhibitory concentration, thereby evaluating the blocking activity of small molecule compounds on BRD4(BD1)/H4 interactions.

IV. Application Strategies of BRD4(BD1)/H4 Binding Assay Kit in Drug Discovery

The BRD4(BD1)/H4 binding assay kit is utilized across multiple critical stages of epigenetic-targeted drug discovery. In small molecule inhibitor screening, the kit can be used to establish high-throughput screening platforms for identifying active compounds that block the interaction between BRD4(BD1) and H4 peptide from large-scale compound libraries. In structure-activity relationship studies, systematic determination of the half-maximal inhibitory concentrations of a series of compounds can reveal patterns between compound structure and activity, guiding structural optimization.

In mechanism-of-action studies, the kit can be used to differentiate the selectivity of compounds for BRD4 BD1 and BD2 domains, aiding researchers in developing subtype-selective inhibitors. In combination therapy studies, it can be used to evaluate synergistic effects between different epigenetic inhibitors. Additionally, the kit can also be used to detect small molecules that enhance the interaction between BRD4(BD1) and H4 peptide, expanding its potential applications in novel drug modalities such as molecular glues.

In experimental design, the following key factors should be considered. The concentrations of BRD4(BD1) protein and H4 peptide should be optimized to ensure the detection system operates within the optimal linear range. Buffer components should avoid substances that interfere with TR-FRET signals. Detection wavelengths and delay times should be set according to the optical properties of the donor-acceptor pair. Furthermore, it is recommended to include positive and negative controls to validate the effectiveness of the experimental system and to avoid interference from compound autofluorescence on detection signals.

V. Conclusion

In practical applications of BRD4(BD1)/H4 binding assays, high-quality detection reagents are crucial for ensuring data reliability and experimental reproducibility. To meet the needs of BRD4(BD1)/H4 interaction evaluation, UniOne offers the UniOne TR-FRET Human BRD4(BD1)/H4 Binding Kit®. This product is based on TR-FRET detection technology and features the following core characteristics: Eu-labeled anti-Tag1 antibody as the donor and Ac-labeled anti-Tag2 antibody as the acceptor, detecting BRD4(BD1) and H4 peptide interactions via a specific 665 nm signal; homogeneous operation mode requiring no washing or separation steps, compatible with high-throughput formats in 96-well and 384-well plates; excellent signal stability, supporting batch processing and flexible time windows; suitable for high-throughput screening of small molecules that can mediate BRD4(BD1) and H4 peptide interactions. This kit is applicable for screening and structure-activity relationship analysis of BRD4 inhibitors, bromodomain selectivity evaluation, and mechanistic studies of epigenetic-targeted drugs.

As a core evaluation tool in epigenetic-targeted drug discovery, the BRD4(BD1)/H4 binding assay kit provides a systematic solution for high-throughput screening of BRD4 inhibitors through its TR-FRET-based homogeneous detection method. From the molecular mechanism of BRD4 bromodomain recognition of acetylated histones to precise quantification of TR-FRET signals, from small molecule inhibitor screening to structure-activity relationship studies, the BRD4(BD1)/H4 binding assay kit continues to play an irreplaceable supporting role. The UniOne TR-FRET Human BRD4(BD1)/H4 Binding Kit® offers a reliable tool for detecting BRD4(BD1)/H4 interactions and will continue to drive innovation in the field of epigenetic-targeted drug development.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next